January 18th 2019EP. 1: Introduction & Physiology of an Asthmatic Episode
January 18th 2019EP. 2: Economic Burden and Type 2 Inflammation in Asthma
January 18th 2019EP. 3: Diagnosis and Biomarkers Tested
January 18th 2019EP. 4: Pharmacologic Treatment Options and Challenges
January 18th 2019EP. 5: Recommended Guidelines and Restrictions in Asthma
January 18th 2019EP. 6: Targeted Pathology and Associated Biomarkers in Asthma
January 18th 2019EP. 7: Biomarkers–Diagnostic Tool for Optimal Therapy
January 18th 2019EP. 8: Challenges of Biologics in the Treatment Plan
January 18th 2019EP. 9: Uncontrolled Severe Asthma and Difference among Biologics
January 18th 2019EP. 10: Omalizumab: Adverse effects, Mechanism, and Patient Factors
January 18th 2019EP. 11: IL-5–Inhibiting Agents Mepolizumab, Benralizumab, and Reslizumab
January 18th 2019EP. 12: Dupilumab: Mechanism, Dosing, and Pivotal Trials
January 18th 2019EP. 13: Experience With Biologics and Pathways
January 18th 2019EP. 14: Severe Patients and Final Thoughts
